Tagged with Opinion,

Opinion Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Here he looks at Novartis’ bold M&A moves and what they could mean for their generics arm, Sandoz.   Besides the large business platform…

Opinion Martin Dewhurst, co-leader for McKinsey’s global Pharmaceuticals and Medical Products Practice, discusses the enormous potential value of digital and analytical advancements for R&D.     One of the areas with the most transformational impact is the potential to double R&D productivity over the next five to ten years.   After years of…

Opinion Mohamed is a passionate Blockchain enthusiast who is committed to helping grow the Blockchain ecosystem around the world. Here he talks about healthcare’s slow adoption of technology and the challenges that come with hefty privacy regulation of patient data.  The life-and-death nature of the industry might be a factor of…

Opinion Richard Saynor, Senior Vice President, Classic and Established Products at GSK urges big pharma to weigh in on improving global health and well-being to achieve the United Nations Sustainable Development Goals.  On the part of pharmaceutical companies, we have a responsibility to help people gain access to high-quality healthcare and…

Canada Brian Hilberdink, President of Novo Nordisk Canada, calls for collaboration between government and industry to ensure that Canadian patients get swift access to the best treatments.    As a Canadian who spent several years working globally for a biopharmaceutical company, I saw firsthand how pricing and investment decisions can be made…

Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here he discusses the new Alma-Ata Declaration that focuses on primary care and work at…

Innovation Richie Etwaru is founder and CEO of Hu-manity, whose vision is to empower people to take ownership of their inherent human data.   The pharmaceutical industry has never seen the full end-to-end benefits of a world where explicitly consented data is available. And this can happen without disruption. Everyone can indeed…

Innovation Axel Schumacher, co-founder and Chief Scientific Officer of Shivom, highlights the need for Big Pharma to adopt new technology. Of course, we know that pharma is often innovation-averse. The healthcare industry has been full of disruptions in the last decade, ranging from the explosive growth of medical devices and the…

Innovation Meghann Chilcott, Senior Vice President of OrderInsite, discusses the changing role of pharmacists and technicians.   Patients are consumers, and they expect more from pharmacies than a collection of pill bottles. Local pharmacists have seen their roles continually change over recent years due to enhanced technology that allows them better…

China Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry.   Napoleon once said: “China is a sleeping giant. Let her sleep, for when she wakes she will shake the world.” Well, in biotech, she is now wide awake I’ve recently returned from…

Medtech Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. He calls for healthcare to be given a new prescription. But, will the private sector write it?   The UK’s National Health Service has crippling sustainability challenges.   With many firms in the midst of or preparing for annual strategic planning sessions, it feels appropriate…

M&A It has been a robust first half in 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities. Deal-tracking sources demonstrate M&A values witnessed meaningful increases in Q2 2018, with deal volumes in the quarter reminiscent of 2016 and 2017 levels [1]. I and others [234] continue…